

WORLD VACCINE



CONGRESS
EUROPE

22ND ANNUAL

19-21 October, 2021

Palau de Congressos de Catalunya
Barcelona, Spain

Research,
Development and
Strategic Partnering
for the Global Vaccine
Industry.

CO-LOCATED WITH

CREATED BY

WORLD VETERINARY
 VACCINE CONGRESS

IMMUNO ONCOLOGY
 PROFILING CONGRESS

SPARK SOMETHING
TERRAPINN 

CONFERENCE TRACKS INCLUDE

WORLD VACCINE  INFLUENZA & RESPIRATORY

WORLD VACCINE  EMERGING & RE-EMERGING

WORLD VACCINE  CLINICAL TRIALS

WORLD VACCINE  BIOPROCESSING & MANUFACTURING

WORLD VACCINE  TECHNOLOGY

WORLD VACCINE  ANTIMICROBIAL RESISTANCE

WORLD VACCINE  PARTNERSHIPS

terrapiinn.com/wvceu-2021prospectus

terrapiinn.com/vetvax-prospectus2021

terrapiinn.com/immuno-prospectus2021/

THE VACCINE INDUSTRY MEETING PLACE

The World Vaccine Congress is an award-winning series of conferences and an exhibition that has grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is shown through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.

Now in its 22nd annual, the World Vaccine Congress Europe, together with the co-located Veterinary Vaccine and Immuno-Oncology congresses, will continue to bring experts from the whole value chain under one roof, where you get to meet decision makers in the areas that are most applicable for your business offering. It will offer the chance to come together at a time where the disruption of COVID-19 has meant being able to network, learn and collaborate is as important as ever.

With 800+ potential customers in attendance there will be opportunities to find contacts who need to find solutions to challenges around the political, commercial and scientific issues in manufacturing, clinical trials, strategy, regulation, veterinary vaccines, immune profiling, AMR, respiratory, influenza, therapeutic and emerging diseases.



150 Speakers

12 Conference Themes

50+ Exhibitors

Workshops

800+ Attendees

Partnering System

CONFERENCE THEMES



Clinical Development



Bioprocessing & Manufacturing



Cancer Immunotherapy



Respiratory & Infectious Diseases



Immune Profiling



Vaccine Safety



Vaccine Partnerships



One Health



Vaccine Supply and Logistics



Biodefence



AMR

EVENT FEATURES:

COVID-19 HUB

A dedicated area for the latest updates and presentations from those leading the race and delivery of a vaccine.

WORLD LEADING PRESENTATIONS

Original presentations from the most informed Industry experts on COVID-19 and all vaccine related topics. Genuine leaders that you can learn from and take away tangible insights for your business.

THE STRONGEST AGENDA YET

Governed by our Scientific Advisory Board, which includes: 23 leading pioneers of the vaccine industry that have ensured the agenda, topics and speakers are relevant and cutting edge, so that your 3 days with us will be the most memorable yet.

INTERNATIONAL DECISION MAKERS

Hear from over 150+ senior speakers across the from the WHO, CEPI, European Commission, EMA, FDA in government to C-level executives from GSK, Merck, Pfizer, Janssen, Sanofi and innovative biotechs. This is your best chance of the year to meet and network with hundreds of like-minded peers at Europe's biggest vaccine meeting.

NEW WORKSHOPS, TRACKS AND TWO CO-LOCATED CONFERENCES

Attend focused sessions across multiple tracks AND two co-located congresses. Take this unique opportunity to gain not only the sessions at the World Vaccine congress, but also the 7th World Veterinary Vaccines Congress and 6th Immuno-Oncology Profiling World Congress.

PANEL DEBATES

We have curated panels of 4-5 industry experts to debate some of your burning questions. You'll be able to watch them live and pose questions directly the panelists.

NETWORKING

There are more networking opportunities, with three days' worth of content, extended breaks, multiple drinks receptions and two co-located events, you will have even more time to meet cross sector contacts with over 800 attendees.

OUR SCIENTIFIC ADVISORY BOARD

WORLD VACCINE
CONGRESS
EUROPE

WORLD VETERINARY
VACCINE CONGRESS

IMMUNO ONCOLOGY
PROFILING CONGRESS



Dr Ofer Levy
Harvard Medical
School



Dr Miles Carroll
Public Health
England



Dr Gregory Poland
Mayo Clinic



Dr Annaliesa Anderson
Pfizer



Prof Hanneke Schuitemaker
Janssen



Prof Albert Osterhaus
RIZ, Hannover
University



Prof Jeffrey Almond
University of Oxford



Dr Jan Poolman
Janssen



Dr Jerald Sadoff
Janssen



Dr Antu Dey
IAVI



Dr Konrad Stradler
CEVA



Dr Roy Baynes
MSD



Dr Nathalie Garcon
Bioaster



Dr Cyril Gay
USDA



Dr Gregory Glenn
Novavax



Prof Stanley Plotkin
Vaxconsult &
University of
Pennsylvania School
of Medicine



Dr Bruce Gellin
Sabin Vaccine
Institute



Dr George Siber
ClearPath



Dr Walter Straus
MSD



Dr Rino Rappuoli
GSK



Dr Mahesh Kuman
Zoetis



Dr Bernard Vallat
Former OIE



Dr Ralf Clemens
GRID Rio



Prof Fred Zepp
University of Mainz



Dr Joris Vandeputte
IABS



Dr Lorne Babiuk
University of Alberta



Dr Maria Elena Bottazzi
Baylor College of
Medicine & Texas
Children's Hospital



Dr Jerome Kim
IVI



Prof Helen McShane
University of Oxford



Dr Lazlo Radvanyi
OICR



Dr Peter Hotez
Baylor College of
Medicine & Texas
Children's Hospital



Dr Christiane Gerke
Institute Pasteur



Dr Leonard Friedland
GSK



Dr Roman Chicz
Sanofi



Prof Mark Davis
Stanford University



Dr Paul Offit
The Children's
Hospital of
Philadelphia



Prof Bali Pulendran
Stanford University



Prof Heidi Larson
LSHTM

TOPICS

Multifaceted technology platforms

- De-risked animal models
- Immune characterisation
- Interplay with T/B cells
- Vaccine & antibody Design



IMMUNO-ONCOLOGY

Technology & delivery platforms

- Companion animal therapeutics
- Adjuvants, mAbs, stem cells
- Cross species technologies
- Therapeutic applicability
- Cancer vaccines
- Animal models

WORLD VACCINE CONGRESS EUROPE



INFECTIOUS & EMERGING DISEASES

- COVID vaccines
- Transboundary diseases
- Antimicrobial resistance
- Autogenous vaccines
- Clinical models
- Technology
- Adjuvants
- Regulation
- One Health
- Disease X



VETERINARY BIOLOGICS

BARCELONA AGENDA OVERVIEW

Oct 19 – 21, 2021

Oct 19 Day 1 CET	KEYNOTES			
9:00 – 9:30	Keynote address: An overview of the UK Covid-19 vaccination programme – from strategy to delivery Dr Jonathan Van Tam, Deputy Chief Medical Officer, England			
9:30 – 10:30	Keynote panel: Efficacy data from COVID vaccines and preparedness for variants - Global vaccine effectiveness rates: Are effectiveness data supporting the efficacy from clinical trials? - What is being seen in vaccine effectiveness data and impact across products and across populations? - How will the different vaccines interact in the immune system? Can we mix & match and is that safe? - Does prevention of transmission and protection against mild disease really matter? - Are we prepared for variants? Dr Kate O'Brien, Director of Vaccines, WHO Dr Matthew Snape, Professor in Paediatrics & Vaccinology, University of Oxford Dr Randall Hyer, Head of Medical Affairs, Moderna Dr Hanneke Schuitemaker, VP, Viral Vaccine Discovery and Translational Medicine, Janssen Vaccines Dr Rino Rappuoli, Chief Scientist, GSK Vaccines Dr Prakash Bhuyan, MD, Vice President, Head of Infectious Diseases, Clinical Development, AstraZeneca			
10:30 – 11:00	Expo & Partnering Morning Break			
11:00 – 12:00	Interactive roundtables			
	Regulatory safety in vaccines - Title TBC Senior representative, SGS	Are we ready and prepared for the upcoming flu season?	Deployment & procurement of COVID vaccines	Next generation vaccines – what will these look like and with what technology?
	Patents and the role of big pharma in and manufacturers during a pandemic – has a new model been built from this experience?	Roundtable title TBC Senior representative, PRA Health Sciences		Currently accepting roundtables Contact Wing-yun.Cheung@Terrapinn.com or Nadia.Konneh@Terrapinn.com
12:00 – 13:30	Expo & Partnering Lunch Break			
Tracks	COVID-19	Clinical Development	Immune Profiling	
Afternoon Sessions	13:30 – 14:30 Panel: How will coronavirus evolve as it establishes itself in the human population? Flu-like, Rhino-like or measles-like? Professor Jeffrey W. Almond PhD, FMedSci. Visiting Professor of Microbiology, University of Oxford	13:30 Use of neutralisation studies to monitor and inform immunisation strategies Dr Nick Gent, Senior Medical Adviser (Emergency Response Department), PHE	13:30 Signatures for distinct disease endotypes and progression to active disease in tuberculosis - Transcriptomic and metabolomic signatures that allow diagnosis and prognosis of tuberculosis - Prognostic markers of progression to active disease will pave the way to	

	Dr Sharon Peacock, Executive Director, COVID-19 Genomics UK (COG-UK) consortium Dr Helena Maier, Group Leader, Coronaviruses, Pirbright		biomarkers which can predict vaccine efficacy Professor Stefan Kaufmann, Director Emeritus, Immunology, Max Planck Institute for Infection Biology
		13:45 Animal Study Reproducibility: Problems and Solutions Eric Ibsen, CEO, Studylog Systems, Inc.	
		14:00 Insights from the world's first COVID-19 human challenge study on young adults – final title TBC Senior representative, hVivo	14:00 Using systems vaccinology/ biology to understand host responses to infection and vaccination - Using next generation b-cell receptor repertoire sequencing technologies to provide in depth knowledge of the diversity of the repertoire
	14:30 UK's data and interpretation from COVID-19 variants Dr Alessandro Carabelli, COVID-19 Genomics UK (COG-UK) consortium	14:30 Developing a Global Informatics Framework In Preparation for Disease X – final title TBC Senior representative, PRA Health Sciences	14:30 Accelerating the next generation of immune medicine with functional phenotyping - title tbc Reserved for IsoPlexis
	15:00 Rapid development to automated scale: Agile response to support SARS-CoV-2 vaccines and therapeutics Dr Luc Gagnon, Vice President, Vaccine Sciences, Nexelis	15:00 Antimicrobial resistance – title TBC Shelley McLendon, Vice President, Vaccine and Infectious Disease, ICON & Caroline Forkin, Vice President, Global Research Services, Government and Public Health Solutions, ICON	15:00 Combining single cell transcriptomics with antibody repertoire sequencing, in order to map the germinal centre response in fine detail - Investigating the human immune system with the tonsil as a model to understand normal immune process Dr Louisa James, Lecturer in Immunology, Blizard Institute, Queen Mary University of London
Afternoon break	15:30 – 16:00 Expo & Partnering Break		
Afternoon Sessions	16:00 Risk Assessment of SARS-CoV-2 variants of interest and impact on vaccine escape Dr Bassam Hallis, Head of Pre-Clinical Dev & General Project Manager, National Infection Service, Public Health England	16:00 The future of vaccine clinical trials in the post-COVID era Martina Kovac, M.D., Vice President, Global Product Development, Vaccines, PPD	Adjuvants
			16:00 Next generation saponin adjuvant: First-in-human clinical trial results Dr Tyler Martin, CEO, Adjuvance Technologies

	16:30 Comparing COVID-19 vaccine schedule combinations - Com-COV2 study findings so far Dr Matthew Snape , Professor in Paediatrics & Vaccinology, University of Oxford	16:30 Presentation title TBC Senior representative, SGS	16:15 Co-development of a GMP emulsion-based adjuvant for human prophylactic vaccines – title tbc Senior representative, SEPPIC
	17:00 – 17:15 Presentation title TBC Senior representative, Luminox	17:00 Successful execution of a Phase 3 COVID-19 vaccine clinical trial – final title TBC Zeil Rosenberg MD, MPH , Medical Director and Therapeutic Area Head- Vaccines, Accelerated Enrollment Solutions (AES)	16:30 Panel: The role of immune profiling platforms in helping us prepare for future pandemics - What can we do in advance to prepare for the next pandemic? - Can we stockpile and amplify? - Can immune profiling platforms help us decide which vaccines to stockpile? - What will the role of adjuvants be in future pandemic preparedness? <i>Panellists to be announced</i>
	17:30 <i>Reserved</i>	17:30 <i>Reserved</i>	
18:00 Sponsored Evening Networking Drinks			
End of day 1			

Oct 20 Day 2	KEYNOTES			
Morning plenary sessions	08:00 – 09:00 Keynote: Impact of mRNA vaccines and new generation of vaccines for the world - What is the future for mRNA vaccines for future pandemics, existing infectious diseases and cancer? - Will RNA vaccines be accessible and sustainably produced for worldwide use? Dr Andreas Kuhn , Senior Vice President RNA Biochemistry & Manufacturing, BioNtech David Hering , Global mRNA Business & Franchise Lead, Pfizer Invited: Moderna & CureVac			
	09:00 – 10:00 Keynote: Should we be vaccinating children with the new COVID vaccines & what is our strategy with other population/age groups? - What do we know about paediatric & maternal immunisation with these new vaccines? - What risk does SARS-Cov-2 pose to the new-born? - Strategy and vaccine considerations to vulnerable groups Dr Gregory Glenn , President R&D, Novavax Dr Randall Hyer , Head of Medical Affairs, Moderna Prof Carl S. Goodyear , Director of GLAZgo Discovery Centre, Senior Senate Assessor on Court, Professor of Translational Immunology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow <i>More speakers to be announced shortly</i>			
Morning break	10:00 – 10:30 Expo & Partnering Break			
Tracks	One Health	AMR & Bacterial Vaccines <i>Chair: Dr Jan Poolman</i> , Head Bacterial Vaccine Discovery	Bioprocess & Manufacturing	Respiratory Diseases

		and Early Development, Janssen		
Afternoon Sessions	10:30 – 11:30 Panel: ZAPI as a model for surge vaccine development and production <i>Moderator: Joris Vandeputte</i> , President, IABS <i>Jean-Christophe Audonnet</i> , Senior Director, Boehringer Ingelheim Animal Health & Coordinator of ZAPI IMI Project <i>Dr Elisabeth Erlacher-Vindel</i> , Head of the Antimicrobial Resistance and Veterinary Products Department, OIE <i>Prof Ab Osterhaus</i> , Director, Research Center For Emerging Infections And Zoonoses (Riz), University of Veterinary Medicine Hannover <i>Stig Tollefsen</i> , Technology Office Lead, CEPI	10:30 WHO strategy, pathogen priorities and role of vaccines <i>Dr Isabel Frost</i> , Consultant, Vaccines and AMR, WHO	10:30 Presentation - title TBC <i>Senior representative, Leukocare</i> 10:45 Large-scale production of subunit vaccines in a bioreactor-free system <i>Dr Jose Escribano</i> , CSO, Algenex	10:30 - 11:30 Panel: Clinical development learnings from COVID-19 <i>Moderator: Dr Jakob Cramer</i> , Head of Clinical Development, CEPI <i>Speakers to be announced</i>
	11:30 Tackling coronaviruses with cross-reactive monoclonal antibodies <i>Dr Berend Jan Bosch</i> , Faculty of Veterinary Medicine, Utrecht University	11:00 – 12:00 CARB-X supported companies and pipeline updates <i>Moderated by Ed Buurman</i> , Alliance Director, CARB-X - GAS <i>Dr Jeff Fairman</i> , Vice President of Research and Founder, VaxCyte - N.gonorrhoeae <i>Dr Calman MacLennan</i> , Professor of Vaccine Immunology, Jenner Institute - Kleb-Acinteo-Pseudo <i>Dr Juanjo Infante</i> , CEO, Vaxdyn	Expediting Viral-Based Vaccines Development in a Pandemic Situation - TBC <i>Senior representative, Sartorius</i>	
	12:00 Combatting Nipah Virus: Developing a vaccine for pigs <i>Dr Dalan Bailey</i> , Group Leader, Cell Biology, Innate Immunity, Molecular Virology, Proteomics, Viral Diseases, The Pirbright Institute	12:00 Epidemiology of bacteremia and sepsis <i>Dr Thomas Verstraeten</i> , CEO, P-95	11:30 Presentation	India's COVID vaccine pipeline
		12:15 E.coli vaccines <i>Dr Jan Poolman</i> , Head Bacterial Vaccine Discovery	12:00 Presentation	12:00 Trial update on Novavax's COVID vaccine <i>Dr Gregory Glenn</i> , President R&D, Novavax

		and Early Development, Janssen		
Lunch Break	12:30 – 14:00 Expo & Partnering Break			
Afternoon Sessions	14:00 – 15:00 Panel: Novel approaches to human and animal vaccine development <i>Moderator: Dr Vish Nene,</i> Co-leader Animal and Human Health program, International Livestock Research Institute Dr Neil King, Assistant Professor, The Institute for Protein Design, University of Washington Prof John Hammond, Group Leader, Genetics, Genomics, Immunology, The Pirbright Institute Fred Fellouse, Senior Research Associate, The Donnelly Centre, University of Toronto	14:00 Presentation: TB 14:15 Presentation: Staph aureus 14:30 Presentation: c.diff Dr Annaliesa Anderson, CSO Bacterial Vaccines, Pfizer	Presentation title TBC Senior representative, Kuhner Shaker COVID case studies: Process development and fixed based reactors - TBC Senior representative, Batavia Biosciences Reserved: ultraDAWN: real-time DSP analytics using light scattering Dr Dan Some, Principal Scientist, Wyatt Technology Corp. Modified vaccinia virus ankara: Platform based development and manufacturing Dr Simone Kardinahl, Vice President Development, IDT Biologika	14:00 COVID vaccine update Dr Hanneke Schuitemaker, VP, Viral Vaccine Discovery and Translational Medicine, Janssen Vaccines 14:30 Are we ready and prepared for the upcoming flu season? Lyn Morgan Marsden, Senior Director Public Affairs, Sanofi & IFPMA Vaccines Committee Chair
	15:00 Safety and immunogenicity of four- segmented Rift Valley fever virus in the common marmoset (Callithrix jacchus) Prof. Dr. Jeroen Kortekaas, Molecular virologist/Group leader, Wageningen Bioveterinary Research	Panel: How do we assess the value of vaccine preventable AMR diseases? - Antibiotic awareness - Future strategy to protect the aging population and pneumococcal vaccinations - How do we assess value? - Economic and public health burden of AMR <i>Moderator:</i> Dr Jan Poolman, Head Bacterial Vaccine Discovery and Early Development, Janssen Dr Mateusz Hasso- Agopsowicz, Technical Officer & Project Manager, Vaccine Product & Delivery Research Immunization, Vaccines and Biologicals (IVB), WHO	Bioprocessing challenges of adjuvanted vaccine development Dr Charles Lutsch, AVP R&D Enabling Sciences & Head Adjuvant Center, Sanofi Pasteur 15:30 – 16:30 Panel: How will we better deliver more sustainable vaccine manufacturing during outbreaks? - How to establish regional health security - The need to develop a long-term manufacturing road map - Identifying manufacturing capacity and capability	15:00 Universal flu vaccines 15:30 RSV vaccines

		Dr Anthony Fiore, MD, MPH, Chief, Epidemiology Research and Innovations Branch, Division of Healthcare Quality Promotion, NCEZID, CDC Dr Charlie Weller, Head of Vaccines, Wellcome Trust	Dr Matthew Downham, Sustainable Manufacturing Lead, CEPI Matthew Duchars, CEO, The Vaccines Manufacturing & Innovation Centre Martin Friede, Coordinator, Initiative for Vaccine Research (IVR), WHO Vivian Hsu, Deputy Director Strategy Planning and Management, Vaccine Development & Surveillance, BMGF	
Break	16:00 – 16:30 Afternoon Expo & Partnering Break			
KEYNOTE				
Closing Plenary	16:30 – 17:30 Keynote panel – how can we better collaborate with a one health approach to prepare for the next pandemic? - What are the next pathogens likely to be? - Will they be Respiratory? Arthropod borne? Faeco-oral? Sexually transmitted? Or antibiotic resistant bacteria? - Making pan-universal vaccines for groups of viruses - Is a 100 day moon-shot timeline achievable for future emerging diseases outbreaks? Dr Josep Jansa, Acting Head of Section Support/Group Leader, Response and Emergency Operations, European Centre for Disease Prevention and Control (ECDC) Dr Dalan Bailey, Group Leader, Cell Biology, Innate Immunity, Molecular Virology, Proteomics, Viral Diseases, The Pirbright Institute Senior representative, WHO Senior representative, CEPI			
	18:00 Sponsored Evening Networking Drinks			
	End of day 2			

DEDICATED TRACK SESSIONS			
Oct 21 Day 3			
9:00 – 9:30	Morning Networking		
Tracks	Emerging Disease X	Immuno-Oncology Profiling	Logistics, Delivery & Access
Morning Sessions	09:30 – 10:30 What's on our priority pathogens list? - Progress on Chik, Nipah, Lassa, Ebola - Investing in research early for non commercial vaccines - Building a sustainable preparedness model Senior representative, WHO	09:30 SARS-CoV-2 vaccines and cancer patients Dr Giuseppe Curigliano, Director, New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology	09:30 Decentralized trials: How to develop a flexible supply chain strategy – Title TBC Senior representative, Marken
			10:00 Presentation – Title TBC David Hipkiss, CEO, Enesi Pharma

	<i>More panellists TBC</i>	10:00 How to match tumour mutanomes to improve immune responses Prof Wim Van Crielinge, CSO, myNEO	10:15 Progress of COVID-19 Vaccines with Needle-Free Delivery Erin Spiegel, VP of Clinical and Regulatory Affairs, Pharmajet
	10:30 Vaxchora® (Cholera Vaccine, live, oral) in Children and Adolescents – A Review Dr Mark Schneider, Sr. Director, Global Medical Affairs - Vaccines and Therapeutics, Emergent Biosolutions	10:30 Panel: Early-stage immuno-oncology clinical trials and the importance of understanding mechanisms in human subjects - Discussing deficiencies in preclinical models - Exploring how newer technologies are powering translational medicine - Designing early-stage studies to maximise the chances of success Moderator: Dr Philip Beer, Physician Scientist And Precision Oncology Specialist, Sanger Institute Dr Giuseppe Curigliano, Director, New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology Katja Rybakova, Founder, Cellgebra & Senior Researcher, Royal College of Surgeons Ireland <i>More panellists to be announced</i>	10:30 Presentation: reserved
	11:00 Progress with malaria vaccination Dr Adrian Hill, Professor, University of Oxford		10:45 A pre-IND versatile nanocomplex formed by electrokinetic force for mRNA vaccine delivery / adjuvant - Delivery with good ordinary cold chain stability and balanced Th1 / Th2 immunogenicity - Formed with bio-degradable materials with clean GLP profile Jason Huang, CMO, Ascendo Biotech
			11:00 Oromucosal vaccine delivery platform Patrik Komárek, Chairman, InStar Technologies 11:15 Presentation: reserved
Break	11:30 – 12:30 Expo & Partnering Brunch Break		
Afternoon Sessions	12:30 – 13:30 Panel: Is it feasible to develop universal/pan corona vaccines? Prof Ab Osterhaus, Director, Research Center For Emerging Infections And Zoonoses (Riz), University of Veterinary Medicine Hannover <i>More panellists to be announced</i>	Therapeutic Vaccines 12:30 Update on Vaccitech's therapeutic hepatitis B program Dr Thomas Evans, CSO & Board Director, Vaccitech 12:50 Progress in combination immunotherapy of cancer involving therapeutic vaccination Cornelis Melief, Chief Scientific Officer, ISA Pharmaceuticals	12:30 – 13:30 Panel: Strengthening immunization programs and recovering routine immunization rates - Vaccine alliances, policy and access - Risks of measles and other vaccine-preventable disease outbreaks re-emerging as a result of un/under-vaccination during the pandemic

		13:10 Developing personalized neoantigen cancer vaccines to target solid tumors Agnete B. Fredriksen, Chief Innovation & Strategy Officer, Vaccibody AS	- Addressing various factors, such as public discomfort in accessing the healthcare system for fear of contracting COVID, disruptions to immunization programs, diversion of staff/resources, etc. Dr Julia Spencer, Associate Vice President, Global Public Policy, MSD Jean-Cédric Meeùs, Chief Transport, UNICEF Supply Division Ingrid Keller, European Commission, Acting Head Chronic Disease and Health Programme Unit, DG Health and Food Safety <i>More panellists to be announced</i>
	13:30 Presentation	13:30 – 14:30 How do we build a better, more successful immuno-oncology clinical development paradigm? - Obstacles in current IO drug & therapeutic development - Discussing how the immuno-oncology field has hit an asymptote in therapeutic gains using the current models of cancer drug development - How can we improve the immuno-oncology drug development pipeline by using earlier stage nimble trials? <i>Moderator: Dr Laszlo Radvanyi</i>, President and Scientific Director, Ontario Institute for Cancer Research Cornelis Melief, Chief Scientific Officer, ISA Pharmaceuticals <i>More panellists to be announced</i>	13:30 – 14:30 Panel: Insights on how to implement new partnership models for international collaboration among vaccine manufacturers, NGOs and government - How do we continue to pursue International collaborative research and partnering opportunities for vaccine development? - What gaps and other challenges do we still face in order to deliver enough COVID vaccines globally? Professor Jeffrey W. Almond PhD FMedSci. Visiting Professor of Microbiology, University of Oxford Dr Satish Ravetkar, Executive Director, Serum Institute of India Jean-Cédric Meeùs, Chief Transport, UNICEF Supply Division <i>More panellists to be announced</i>
	14:00 Presentation		
Break	14:30 – 15:00 Expo & Partnering Afternoon Break		
KEYNOTE			
Closing Plenary	15:00 – 16:00 Vaccine confidence: What has the uptake of our COVID vaccines been globally? - When will the majority of the population be vaccinated and protected from COVID? - What hurdles do we face that could prevent us from achieving our goals? - Why are there such differences between countries? Has vaccine distribution been fair? - Tackling misinformation		

- The impact of the pandemic on routine immunization programs

Dr Heidi Larson, Professor of Anthropology, Risk and Decision Science, **LSHTM**

Dr John Markels, President of Global Vaccines, **MSD**

Dr Thomas Breuer, CMO, **GSK Vaccines**

Lisa Menning, Technical Officer (Department of Immunization, Vaccines, and Biologicals), **WHO**

Isabel de la Mata, Principal Advisor for Health and Crisis management, **European Commission, DG Health and Food Safety**

16:00 End of congress



EVENT TEAM

SPEAKING OPPORTUNITIES

Wing-Yun Cheung

wing-yun.cheung@terrapinn.com

Nadia Konneh

nadia.konneh@terrapinn.com

SPONSORSHIP & EXHIBITION

Marc Rhys- Evans

marc.rhys-evans@terrapinn.com

Oliver Breed

oliver.breed@terrapinn.com

MARKETING OPPORTUNITIES

Karina Kusova

Karina.kusova@terrapinn.com
